FDA calls Novo Nordisk's Wegovy pill ad false or misleading

The U.S. Food and Drug Administration has told Novo Nordisk that a television ad for its oral Wegovy (semaglutide) tablets is "false or misleading," in an untitled letter dated February 5, 2026 ^[1]. The agency said the spot misbrands the drug and makes its distribution a violation of the Federal Food, Drug, and Cosmetic Act, and asked the company to take immediate action, including possibly pulling ads with similar claims ^[1][2].

The letter, from FDA's Office of Prescription Drug Promotion, targets a direct-to-consumer commercial called "January 2026 Pill Spot" ^[1]. Reviewers quoted lines from the voiceover, including "The first and only FDA approved GLP-1 weight loss pill," "Weight loss with Wegovy isn't a shortcut. It's a way forward," and "Now you can live lighter by losing weight," along with on-screen text reading "LIVE LIGHTER by losing weight and keeping it off" ^[1].

What the FDA objected to

FDA said the combination of those claims suggests that, because Wegovy now comes as a pill, it offers "superior efficacy and/or safety" over other approved GLP-1 weight-loss treatments, and that the pill "uniquely enables patients to achieve outcomes that were not previously possible" with other GLP-1 drugs ^[1]. The phrases "live lighter" and "a way forward" imply more weight loss than other GLP-1s, "when this has not been demonstrated," the agency wrote ^[1].

The letter also faulted the ad for implying "benefits beyond physical weight loss such as emotional relief, reduced psychological burden, hope, or direction for patients' lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific condition, when this has also not been demonstrated" ^[1].

FDA pointed to the approved prescribing information, which describes the 25 mg once-daily oral tablet as having been evaluated in a placebo-controlled trial — that is, against placebo, not against other GLP-1 medicines ^[1]. "FDA is not aware of data to support the implication that Wegovy, in pill form, is superior to other currently approved GLP-1 treatments," the letter said, inviting Novo to submit supporting data if it has any ^[1].

Separately, the agency flagged a technical problem: the ad's major statement of risks included on-screen text (SUPERs) that did not match the audio, so the ad failed to present risk information concurrently in both audio and text, a requirement known as dual modality ^[1][2].

The ad is part of Novo's "Live lighter" campaign and first aired during the Golden Globes on January 11, 2026, according to The BMJ ^[3]. Novo Nordisk confirmed receiving the letter and said the ad had been running since the pill's launch and was not the company's Super Bowl spot. "We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement's presentation," said Liz Skrbkova, Novo's head of U.S. media and stakeholder relations ^[2].

Why it matters for patients

Millions of Americans see GLP-1 ads. This letter is a reminder that a marketing claim is not the same as a tested result. The oral Wegovy trial cited in the label compared the pill to placebo, so nothing in it establishes that the pill produces more weight loss than injectable semaglutide, tirzepatide (Mounjaro/Zepbound), or any other approved GLP-1 ^[1].

The emotional framing matters too. FDA specifically said suggestions of "hope" or relief from life's broader burdens have not been demonstrated for this drug ^[1]. Whether the pill's different route of administration changes side effects or results compared with injections is not addressed by the letter.

The dual-modality issue is also practical: risk information in TV ads is supposed to be both said out loud and shown, so viewers can absorb it either way ^[1].

The stakes are commercial. The pill launched in the U.S. in January 2026 as the first GLP-1 pill for obesity, and Novo said in early February that more than 170,000 American patients were already taking it ^[2]. By its second-quarter report, Novo said the pill had passed 5 million prescriptions, with about 80% of users new to GLP-1 therapy ^[4].

What happens next

FDA asked Novo Nordisk to respond in writing within 15 working days of receiving the February 5 letter, listing all promotional materials with similar claims and explaining how it will discontinue them — or to explain why it believes the ad complies with the law ^[1]. The agency noted its concerns are "not necessarily" an exhaustive list of potential violations ^[1]. On February 9, Novo also sued telehealth company Hims & Hers over marketing of compounded versions of Wegovy ^[2].